Abart 60mg Injection

Introduction

Abart is a prescription medication that contains the active ingredient Artesunate. It is available under the brand name Abart. This medication is primarily used for the treatment of severe malaria.

Uses

Abart is prescribed for the treatment of severe malaria caused by Plasmodium falciparum, a parasite transmitted through mosquito bites. It is an effective antimalarial medication that is used when the infection is severe or when the parasite is resistant to other antimalarial drugs.

Dosage and Administration

Abart should be administered under the supervision of a healthcare professional. The dosage and duration of treatment may vary depending on the severity of the infection and the patient’s age and weight. It is typically given by intravenous infusion.

The exact dosage and administration instructions will be determined by your healthcare provider. Follow their instructions carefully and complete the full course of treatment as prescribed.

Mechanism of Action

Artesunate, the active ingredient in Abart, belongs to a class of medications known as artemisinin derivatives. It works by damaging the parasite’s cell membranes, leading to the destruction of the parasite. This mechanism of action helps in reducing the number of parasites in the blood, thereby treating the infection.

Side Effects

Common side effects may include nausea, vomiting, headache, dizziness, and abdominal pain. These side effects are usually mild and temporary.

However, there are some serious side effects that may occur. These can include severe allergic reactions, such as difficulty breathing, swelling of the face or throat, or rash. If you experience any of these serious side effects, seek immediate medical attention.

Drug Interactions

inform your healthcare provider about all the medications you are currently taking, including prescription, over-the-counter, and herbal products. Certain medications may interact with Abart, potentially affecting its effectiveness or increasing the risk of side effects.

Some common drug interactions may include certain anticoagulants, anticonvulsants, and antiretroviral medications. Discuss any potential drug interactions with your healthcare provider before starting treatment with Abart.

Precautions

Before using Abart, inform your healthcare provider about any medical conditions you have, especially if you have a history of liver or kidney disease. This medication should be used with caution in patients with pre-existing conditions.

Abart is not recommended for use during pregnancy unless absolutely necessary. Discuss the risks and benefits of using this medication with your healthcare provider if you are pregnant or planning to become pregnant.

Storage

Patient Tips

• complete the full course of treatment as prescribed by your healthcare provider, even if you start feeling better before the treatment is finished.
• If you experience any unusual or bothersome side effects, contact your healthcare provider immediately.
• Practice good mosquito bite prevention measures, such as using insect repellents, wearing protective clothing, and using bed nets, to reduce the risk of malaria infection.
• Follow your healthcare provider’s instructions regarding follow-up appointments and any additional tests that may be required.
• Do not share needles or syringes with others to prevent the spread of infections.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Artesunate (Drugs.com) [Accessed 28 Jun. 2024] (online) Available at:
• artesunate 110 mg intravenous solution antimalarial drugs (RX) [Accessed 3 Jun. 2024] (online) Available at:
• Malaria (MedlinePlus) [Accessed 29 Jun. 2024] (online) Available at:
• Li ZJ, Dai HQ, Huang XW, Feng J, Deng JH, Wang ZX, Yang XM, Liu YJ, Wu Y, Chen PH, Shi H, Wang JG, Zhou J, Lu GD. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Acta Pharmacol Sin. 2021 Feb;42(2):301-310. doi: 10.1038/s41401-020-0478-3. Epub 2020 Jul 22. [Accessed 1 Jun. 2024] Available at: